Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Cecilia Larocca, M.D.

Title
Institution
Department
Address

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Gupta N, Virgen CA, Goyal A, Lane AA, Antin JH, Divito SJ, Larocca C. Novel use of acitretin for posttransplant Grover's disease and cutaneous graft versus host disease. JAAD Case Rep. 2023 Mar; 33:67-69. PMID: 36890866; PMCID: PMC9988423.
    Citations:    
  2. Fay CJ, Awh KC, LeBoeuf NR, Larocca CA. Harnessing the immune system in the treatment of cutaneous T cell lymphomas. Front Oncol. 2022; 12:1071171. PMID: 36713518; PMCID: PMC9878398.
    Citations:    
  3. Jfri A, Smith JS, Larocca C. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review. J Am Acad Dermatol. 2022 Dec 05. PMID: 36481378.
    Citations:    Fields:    
  4. Yeh JE, Lorenzo ME, Larocca C, Fisher DC, Foreman RK. Small lymphocytic lymphoma presenting as chronic diffuse lip swelling. Dermatol Online J. 2022 Oct 15; 28(5). PMID: 36809138.
    Citations:    Fields:    Translation:Humans
  5. Zagona-Prizio C, Yousif J, Grant C, Mehta M, Rosmarin D, Silverberg N, Tan J, Larocca C, Shinohara M, Mostaghimi A, Kim B, Gulliver S, Gulliver W, Siegel D, Perez-Chada L, Merola J, Gottlieb A, Armstrong A. International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting. J Drugs Dermatol. 2022 Aug 01; 21(8):867-874. PMID: 35946973.
    Citations:    Fields:    Translation:Humans
  6. Plumptre IR, Said JT, Sun T, Larocca C, Virgen CA, Kupper TS, Fisher DC, Devlin PM, Elco CP, Song JS, LeBoeuf NR. Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review. Leuk Lymphoma. 2022 12; 63(12):2832-2846. PMID: 35862569.
    Citations:    Fields:    Translation:HumansCells
  7. Larocca C, Shanmugam V, Zemmour D, Antin JH, Lane AA. Shared Clonal Origin of Multiple Histiocytic and Dendritic Neoplasms and Polycythemia Vera, Follicular Lymphoma in 1 Patient. Am J Dermatopathol. 2022 12 01; 44(12):929-932. PMID: 35642960.
    Citations:    Fields:    Translation:HumansCells
  8. Yu KK, Smith NP, Essien SV, Teague JE, Vieyra-Garcia P, Gehad A, Zhan Q, Crouch JD, Gerard N, Larocca C, Wolf P, LeBoeuf NR, Tawa M, Kupper TS, Villani AC, Clark RA. IL-32 Supports the Survival of Malignant T Cells in Cutaneous T-cell Lymphoma. J Invest Dermatol. 2022 08; 142(8):2285-2288.e2. PMID: 35143819; PMCID: PMC9329172.
    Citations:    Fields:    Translation:HumansCells
  9. Bui AN, Larocca C, Giobbie-Hurder A, Jacobsen ED, LeBoeuf NR. Cutaneous Langerhans cell histiocytosis in adults: A retrospective cohort study of adult patients presenting to a single academic cancer center between 2003 and 2017. J Am Acad Dermatol. 2022 06; 86(6):1413-1416. PMID: 34119604.
    Citations:    Fields:    Translation:Humans
  10. Larocca CA, LeBoeuf NR, Silk AW, Kaufman HL. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions. Am J Clin Dermatol. 2020 Dec; 21(6):821-832. PMID: 32767272.
    Citations: 9     Fields:    Translation:HumansCells
  11. Bui AN, Singer S, Hirner J, Cunningham-Bussel AC, Larocca C, Merola JF, Lian CG, LeBoeuf NR. De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysis. J Am Acad Dermatol. 2021 Mar; 84(3):864-869. PMID: 33323344.
    Citations: 3     Fields:    Translation:Humans
  12. Bui AN, Hirner J, Singer SB, Eberly-Puleo A, Larocca C, Lian CG, LeBoeuf NR. De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation. Clin Exp Dermatol. 2021 Mar; 46(2):328-337. PMID: 32939795.
    Citations: 4     Fields:    Translation:Humans
  13. O'Malley JT, de Masson A, Lowry EL, Giobbie-Hurder A, LeBoeuf NR, Larocca C, Gehad A, Seger E, Teague JE, Fisher DC, Kupper TS, Devlin PM, Clark RA. Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. Clin Cancer Res. 2020 01 15; 26(2):408-418. PMID: 31636100.
    Citations: 2     Fields:    Translation:HumansCells
  14. Larocca C, Kupper TS, LeBoeuf NR. Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem. Clin Cancer Res. 2019 12 15; 25(24):7272-7274. PMID: 31615932.
    Citations: 1     Fields:    Translation:Humans
  15. Larocca CA, LeBoeuf NR. Overview of Cutaneous T-Cell Lymphomas. Hematol Oncol Clin North Am. 2019 08; 33(4):669-686. PMID: 31229162.
    Citations: 2     Fields:    Translation:Humans
  16. LeBoeuf NR, Larocca C. Cutaneous Malignancy. Hematol Oncol Clin North Am. 2019 02; 33(1):xv-xvi. PMID: 30497681.
    Citations:    Fields:    
  17. Larocca C, Kupper T. Mycosis Fungoides and Sézary Syndrome: An Update. Hematol Oncol Clin North Am. 2019 02; 33(1):103-120. PMID: 30497668; PMCID: PMC7147244.
    Citations: 20     Fields:    Translation:HumansCells
  18. Yan G, Eller MS, Elm C, Larocca CA, Ryu B, Panova IP, Dancy BM, Bowers EM, Meyers D, Lareau L, Cole PA, Taverna SD, Alani RM. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol. 2013 Oct; 133(10):2444-2452. PMID: 23698071; PMCID: PMC4380234.
    Citations: 53     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Larocca's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (95)
Explore
_
Co-Authors (23)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.